Sandra Lamy, Pharm D, is an accomplished regulatory lead in the oncology sector, currently seeking new opportunities after a successful tenure at Gilead Sciences. Previously, Sandra served as Asset Evaluation & Strategy Director at Servier, where they specialized in the strategic evaluation of oncology assets. They have extensive experience in regulatory affairs, having held positions at Sanofi-Aventis and Stallergenes Greer, among others. Sandra holds a Doctor of Pharmacy degree from the Faculté de Pharmacie de Tours and is pursuing additional studies at the University of Tours.
This person is not in the org chart
This person is not in any teams
This person is not in any offices